Protara Presenting Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 at SUO

December 5, 2024

DENVER, Colo., Dec 05, 2024 (247marketnews.com)- Protara Therapeutics (NASDAQ: TARA) presented results from its ongoing Phase 2 open-label ADVANCED-2 trial, assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve.

TARA-002 demonstrated a complete response (CR) rate across BCG exposures of 72% (13/18) at six months and 70% (14/20) at any time with 100% (9/9) of patients maintaining a CR from three months to six months, while two of three patients maintained a CR at nine months.

These results will be featured, during a poster session, at the 25th Annual Meeting of the Society of Urologic Oncology (SUO) in Dallas, Texas.

Brian Mazzarella, MD, Urology America’s Vice President of Research and ADVANCED-2 study investigator, exclaimed, “These impressive TARA-002 results demonstrate meaningful activity in a difficult to treat patient population. The activity of TARA-002 across BCG exposures, coupled with its ease of use and low procedural burden for physicians, make it an exciting potential treatment option for NMIBC patients.”

Jesse Shefferman, CEO of Protara Therapeutics, added, “We are thrilled with these positive six-month data, which reinforce TARA-002’s potential in NMIBC, while offering a compelling product profile for physicians and patients. We believe these encouraging data together with our international site expansion will accelerate patient enrollment, and we look forward to reporting initial data from 12-month evaluable patients in mid-2025.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (TARA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.